KromaTiD Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

KromaTiD General Information

Description

Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases. The company's molecular cytogenetic and GeneTracker tests discover, detect, and diagnose the widest range of disease-causing mutations, including inversions and translocations, in a single test, enabling research teams in academia, pharma, and biopharma to accelerate the delivery of novel therapeutics to the patients who need them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6899 Winchester Cir
  • Street 100
  • Boulder, CO 80301
  • United States
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • 6899 Winchester Cir
  • Street 100
  • Boulder, CO 80301
  • United States

KromaTiD Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KromaTiD Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Secondary Transaction - Private 15-Feb-2026 Completed Generating Revenue
14. Later Stage VC (Series C) 10-Jul-2025 Completed Generating Revenue
13. Later Stage VC (Series B) 15-Oct-2021 Completed Generating Revenue
12. Grant 15-Jan-2021 Completed Generating Revenue
11. Grant 04-Aug-2020 Completed Generating Revenue
10. Debt - PPP 15-Apr-2020 Completed Generating Revenue
9. Later Stage VC (Series A1) 12-Sep-2019 Completed Generating Revenue
8. Grant 10-Jun-2019 Completed Generating Revenue
7. Debt - General 01-Dec-2018 $800K $5.8M Completed Generating Revenue
6. Later Stage VC (Series A) 31-May-2017 $5M $5M Completed Generating Revenue
To view KromaTiD’s complete valuation and funding history, request access »

KromaTiD Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A1 3,850,000 $0.5 $0.5 1x $0.5 5.92%
Series A 12,247,955 $0.27 $0.27 1x $0.27 18.84%
To view KromaTiD’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

KromaTiD Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in t
Biotechnology
Boulder, CO
35 As of 2025

Pacheco, CA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

KromaTiD Competitors (48)

One of KromaTiD’s 48 competitors is Biocare Medical (Discovery Tools), a Formerly PE-Backed company based in Pacheco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocare Medical (Discovery Tools) Formerly PE-Backed Pacheco, CA
Mission Bio Venture Capital-Backed San Francisco, CA
Arbor Biotechnologies Venture Capital-Backed Cambridge, MA
Deep Genomics Venture Capital-Backed Toronto, Canada
GemPharmatech Formerly VC-backed Nanjing, China
You’re viewing 5 of 48 competitors. Get the full list »

KromaTiD Patents

KromaTiD Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4347876-A1 Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number Active 22-Apr-2022
EP-4347876-B1 Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number Active 22-Apr-2022
EP-4570920-A2 Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number Pending 22-Apr-2022
EP-4570920-A3 Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number Pending 22-Apr-2022
US-20260132446-A1 Methods, compositions, and kits for determining chromosome stability, genotoxicity, and insert number Pending 22-Apr-2022 C12Q1/6827
To view KromaTiD’s complete patent history, request access »

KromaTiD Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KromaTiD Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
BroadOak Capital Partners Growth/Expansion Majority
National Institutes of Health Government
First Capital Ventures Venture Capital Minority
U.S. Department of Health and Human Services Government
Innosphere Ventures Accelerator/Incubator Minority
You’re viewing 5 of 7 investors. Get the full list »

KromaTiD FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process